R1 RCM (NASDAQ:RCM) was upgraded by equities research analysts at BidaskClub from a “hold” rating to a “buy” rating in a research note issued on Thursday.
RCM has been the subject of several other research reports. Zacks Investment Research upgraded R1 RCM from a “strong sell” rating to a “hold” rating in a research note on Wednesday, October 4th. Robert W. Baird restated a “hold” rating and issued a $5.00 price target on shares of R1 RCM in a research note on Tuesday, September 26th.
R1 RCM (NASDAQ RCM) traded up $0.14 during mid-day trading on Thursday, hitting $4.40. The stock had a trading volume of 216,043 shares, compared to its average volume of 209,218. R1 RCM has a 52-week low of $2.02 and a 52-week high of $4.64. The stock has a market capitalization of $451.38, a PE ratio of -15.71 and a beta of -0.48.
ILLEGAL ACTIVITY NOTICE: “R1 RCM (RCM) Upgraded to “Buy” by BidaskClub” was first posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this story on another site, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be read at https://stocknewstimes.com/2018/01/12/r1-rcm-rcm-upgraded-to-buy-by-bidaskclub.html.
R1 RCM Company Profile
R1 RCM Inc, formerly Accretive Health, Inc, is a provider of revenue cycle management (RCM) and physician advisory services (PAS) to healthcare providers. The Company is engaged in providing management services of revenue cycle operations for the United States-based hospitals and other medical services providers.
Receive News & Ratings for R1 RCM Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for R1 RCM and related companies with MarketBeat.com's FREE daily email newsletter.